Harvard Apparatus Regenerative Tech Inc (HART) Shares up As CEO Plans to Present at LD Micro “Main Event” investor conference

Share

Shares of Harvard Apparatus Regenerative Tech Inc (NASDAQ:HART) are soaring today as the company’s CEO Jim McGorry plans to present at the LD Micro “Main Event” investor conference tomorrow at 2:30 p.m. PT.

According to the company the conference, which is being held at the Luxe Sunset Bel Air Hotel in Los Angeles will be webcast live at the following url: http://wsw.com/webcast/ldmicro9/hart

Shareholders are hoping for steady progress to be revealed by the company whose main line of business involves the development of bioengineered organ implants for transplantation.The stock is up 28.64% or $0.63 after the news, hitting $2.83 per share. About 10.18 million shares traded hands or 478.41% up from the average. HART has declined 25.17% since April 27, 2015 and is downtrending. It has underperformed by 24.28% the S&P500.

The institutional sentiment increased to 0.76 in Q2 2015. Its up 0.11, from 0.65 in 2015Q1. The ratio improved, as 8 funds sold all Harvard Apparatus Regenerative Tech Inc shares owned while 9 reduced positions. 3 funds bought stakes while 10 increased positions. They now own 2.64 million shares or 18.87% less from 3.26 million shares in 2015Q1.

Penbrook Management Llc holds 0.17% of its portfolio in Harvard Apparatus Regenerative Tech Inc for 126,583 shares. Sio Capital Management Llc owns 232,712 shares or 0.16% of their US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.01% invested in the company for 195,915 shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.01% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 21,833 shares.

Since September 21, 2015, the stock had 1 buying transaction, and 0 sales for $12,210 net activity. Lafrancesca Saverio bought 9,500 shares worth $12,210.

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology firm making regenerated organs for transplant. The company has a market cap of $29.08 million. The Company’s product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea . It currently has negative earnings. The HART-Trachea comprises the patient’s own bone marrow cells seeded on the Company’s InBreath porous plastic scaffold in its InBreath organ bioreactor.

COMMENTS: